BidaskClub Downgrades Orthopediatrics (KIDS) to Hold

Orthopediatrics (NASDAQ:KIDS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

Other equities analysts have also issued research reports about the company. ValuEngine raised Orthopediatrics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. William Blair reissued an “outperform” rating on shares of Orthopediatrics in a research note on Wednesday, June 27th. Piper Jaffray Companies boosted their price objective on Orthopediatrics from $24.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, July 5th. Finally, Zacks Investment Research raised Orthopediatrics from a “sell” rating to a “hold” rating in a research note on Friday, May 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Orthopediatrics presently has a consensus rating of “Buy” and an average target price of $25.67.

NASDAQ KIDS traded down $0.08 on Wednesday, reaching $27.75. 49 shares of the company were exchanged, compared to its average volume of 55,944. The firm has a market capitalization of $346.00 million and a P/E ratio of -4.87. The company has a debt-to-equity ratio of 0.57, a quick ratio of 4.16 and a current ratio of 6.24. Orthopediatrics has a fifty-two week low of $14.00 and a fifty-two week high of $31.39.

Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). The business had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.27 million. The company’s revenue for the quarter was up 28.0% on a year-over-year basis. sell-side analysts forecast that Orthopediatrics will post -0.76 EPS for the current year.

In other Orthopediatrics news, Director David R. Pelizzon bought 2,000 shares of Orthopediatrics stock in a transaction on Tuesday, May 22nd. The shares were bought at an average price of $19.50 per share, for a total transaction of $39,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 46.10% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of KIDS. BlackRock Inc. purchased a new stake in Orthopediatrics in the fourth quarter valued at $3,776,000. Deutsche Bank AG purchased a new stake in Orthopediatrics in the fourth quarter valued at $196,000. Teachers Advisors LLC purchased a new stake in Orthopediatrics in the fourth quarter valued at $102,000. TIAA CREF Investment Management LLC purchased a new stake in Orthopediatrics in the fourth quarter valued at $130,000. Finally, Wasatch Advisors Inc. raised its position in Orthopediatrics by 46.3% in the first quarter. Wasatch Advisors Inc. now owns 235,815 shares of the company’s stock valued at $3,551,000 after purchasing an additional 74,666 shares during the period. Institutional investors own 35.35% of the company’s stock.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

See Also: Diversification Important in Investing

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply